Price
CHART BY
Frequently asked questions
What is Arcturus's market capitalization?
The market capitalization of Arcturus is $481.34M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Arcturus?
Arcturus's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.213. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Arcturus's stock?
Currently, 11 analysts cover Arcturus's stock, with a consensus target price of $76.32. Analyst ratings provide insights into the stock's expected performance.
What is Arcturus's revenue over the trailing twelve months?
Over the trailing twelve months, Arcturus reported a revenue of $145.60M.
What is the EBITDA for Arcturus?
Arcturus's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$26.93M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Arcturus?
Arcturus has a free cash flow of -$61.26M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Arcturus have, and what sector and industry does it belong to?
Arcturus employs approximately 180 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Arcturus's shares?
The free float of Arcturus is 24.34M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $481.34M
- EPS (TTM)
- -$2.213
- Free Float
- 24.34M
- Revenue (TTM)
- $145.60M
- EBITDA (TTM)
- -$26.93M
- Free Cashflow (TTM)
- -$61.26M
Pricing
- 52W span
- $14.30$44.99
Analyst Ratings
The price target is $76.32 and the stock is covered by 11 analysts.
Buy
11
Hold
0
Sell
0
Information
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
- Employees
- 180
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US03969T1097
- Primary Ticker
- ARCT
Finance data from FactSet